| __timestamp | Halozyme Therapeutics, Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 2395000 |
| Thursday, January 1, 2015 | 29245000 | 9057000 |
| Friday, January 1, 2016 | 33206000 | 393000 |
| Sunday, January 1, 2017 | 31152000 | 79309000 |
| Monday, January 1, 2018 | 10136000 | 134428000 |
| Tuesday, January 1, 2019 | 45546000 | 175431000 |
| Wednesday, January 1, 2020 | 43367000 | 124165000 |
| Friday, January 1, 2021 | 81413000 | 121875000 |
| Saturday, January 1, 2022 | 139304000 | 10114000 |
| Sunday, January 1, 2023 | 192361000 | 9206000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart offers a fascinating glimpse into the cost of revenue trends for Halozyme Therapeutics, Inc. and Wave Life Sciences Ltd. over the past decade. From 2014 to 2023, Halozyme's cost of revenue surged by approximately 747%, peaking in 2023. In contrast, Wave Life Sciences experienced a more volatile trajectory, with a significant spike in 2019, followed by a sharp decline in 2022.
These trends highlight the contrasting strategies and market responses of these two biotech firms, offering valuable insights for industry analysts and investors.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Wave Life Sciences Ltd.'s Expenses
Cost Insights: Breaking Down Exelixis, Inc. and Wave Life Sciences Ltd.'s Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Wave Life Sciences Ltd.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.